Tajikistan Medical Device Variations and Re-registration: Dossier Updates and Timing Strategy

1. Key takeaways

For variations and re-registration in Tajikistan, the procedures are established and approved by the authorised state body in the field of health. Article 17(10) of Law No. 1893 provides that the procedures for re-registration of medicines and for making changes and additions to the submitted documents are established and approved by the authorised state body in the field of health; Article 17(12) provides that the procedures for registration and re-registration of medical devices and parapharmaceuticals, and for making changes and additions to the submitted documents, are likewise established and approved by that body. GRZAN notes that the law only provides the authorisation pathway: the classification of variations, the time limits and the documentation requirements are all found in the procedural documents of the Ministry of Health. In addition, the widely circulated claim that re-registration must be submitted three months before expiry is marked by us as a practical estimate – Law No. 1893 does not prescribe any lead time.

2. Legal basis

3. Expert insights

Insight 1: The separate listing of Article 17(10) and Article 17(12) is a legislative technique that recurs throughout this series. Paragraph 10 addresses medicines, and paragraph 12 addresses medical devices and parapharmaceuticals; both point to the power of the Ministry of Health to establish and approve procedures. GRZAN reads this as a deliberate choice by the legislator to keep the procedural documents for devices independent of those for medicines, leaving room for the device procedure to diverge from the medicine procedure over time. When requesting the documents, companies must explicitly indicate medical devices in their request.

Insight 2: The law does not prescribe a lead time for re-registration, and this is the source of scheduling risk. Article 17 of Law No. 1893 speaks of re-registration but never says when the application must be filed. The circulating figure of three months before expiry comes from consulting experience and is marked by us as a practical estimate. GRZAN works backwards from Article 21(1)(3): that provision lists, among the grounds for withdrawal from circulation, products whose registration and re-registration periods have expired before importation into Tajikistan. Because Tajik review carries no statutory time limit (neither Article 17 nor Article 18 contains one), the lead time should be calculated as review cycle plus transport cycle plus a safety margin, rather than by applying a fixed three months.

Insight 3: The trigger points for variations are scattered across several provisions and require a consolidated list. GRZAN has mapped at least five categories of variation triggers: changes to product technical specifications (the quality documents under Article 16(7)); updates to the instructions for use (Article 21(1)(6) and (7)); changes of manufacturer or manufacturing site (contract manufacturing under Article 1(25)); changes to the registration status in the country of origin (the certificates under Article 17(2)); and changes to the product name (Article 1(32)). We recommend turning these five categories into a variation trigger list and embedding it in the change control procedure.

Insight 4: The register information under Article 17(8) also needs to be updated in step. The provision requires the supervisory authority to enter the list of registered products into the State Register of Medicines. When the certificate holder information, product name, model or similar details change, the register information should be updated accordingly. GRZAN recommends verifying after each approved variation whether the register has been synchronised, so that discrepancies between the certificate and the register do not accumulate unnoticed.

Insight 5: The publication mechanism of Article 44(5) makes variations and market withdrawals externally visible. The provision requires information on registration and cancellation of registration to be published by the supervisory authority in the relevant publications. The implication is that a variation or a withdrawal is not an internal matter but public information. Companies handling variations should plan external communication at the same time, especially where the change involves a product withdrawal or a restriction on circulation.

4. Practical recommendations

1. Request the current procedural documents before every variation or re-registration. Under Article 17(12), request the version covering medical devices and parapharmaceuticals explicitly, and keep it distinct from the medicines version under paragraph 10.
2. Schedule the re-registration start date by working backwards from review cycle plus transport cycle plus a safety margin. Under Article 21(1)(3), do not apply a fixed three-month lead time; calculate from actual cycle times and keep a buffer.
3. Build a variation trigger list covering five categories. Cover technical specifications, instructions for use, manufacturer and manufacturing site, registration status in the country of origin, and product name; embed the list in the change control procedure and appoint owners.
4. Verify register synchronisation after every approved variation. Under Article 17(8), check after each approval whether the State Register of Medicines has been updated, and keep records of the queries.
5. Include external communication for variations and withdrawals in the contingency plan. Under Article 44(5), for changes involving withdrawal or restriction of circulation, prepare the external messaging and channel plan at the same time as the filing.

5. Verification checklist

• □ Obtained the current procedural documents for variations and re-registration of medical devices (Article 17(12))
• □ Scheduled the re-registration start date by working backwards from review cycle plus transport cycle plus a safety margin
• □ Built a variation trigger list covering technical specifications, instructions for use, manufacturer and site, country-of-origin status, and product name
• □ Verified the synchronisation of the register information under Article 17(8) after every approved variation
• □ Confirmed that the withdrawal risk under Article 21(1)(3) is factored into the schedule calculation
• □ Included the publication mechanism of Article 44(5) in the external communication plan for variations and withdrawals
• □ Confirmed that the requested procedural documents are the medical device version, not the medicines version (Article 17(10))

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN focus on three points. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a choice exists between a national pathway and a Union pathway; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan are outside the Union framework and must follow purely national procedures. Second, local authorised representative services: GRZAN can act as the statutory representative of manufacturers in the above countries, undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN assists in establishing a quality management system conforming to ISO 13485 and connects clients with locally accredited laboratory resources.

For business inquiries: info@grzanglobal.com